Anebulo Pharmaceuticals, Inc.
ANEB
$1.14
$0.065.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -19.45% | -13.84% | -18.98% | -48.39% | -12.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.24% | -5.17% | -46.26% | -41.89% | -27.60% |
| Operating Income | 6.24% | 5.17% | 46.26% | 41.89% | 27.60% |
| Income Before Tax | 9.36% | 11.29% | 45.90% | 40.90% | 28.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.36% | 11.29% | 45.90% | 40.90% | 28.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.36% | 11.29% | 45.90% | 40.90% | 28.99% |
| EBIT | 6.24% | 5.17% | 46.26% | 41.89% | 27.60% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 14.80% | 12.29% | 46.51% | 41.58% | 29.40% |
| Normalized Basic EPS | 14.72% | 12.40% | 46.55% | 41.50% | 29.37% |
| EPS Diluted | 14.80% | 12.29% | 46.51% | 41.58% | 29.40% |
| Normalized Diluted EPS | 14.72% | 12.40% | 46.55% | 41.50% | 29.37% |
| Average Basic Shares Outstanding | 6.30% | 1.17% | 1.17% | 1.17% | 0.61% |
| Average Diluted Shares Outstanding | 6.30% | 1.17% | 1.17% | 1.17% | 0.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |